Contact us: +91 9550333722 040 - 40102781
Structured search
India
Choose your country
Different countries will display different contents
Try our best to find the right business for you.
My chemicalbook

Welcome back!

HomeProduct name listHALOFANTRINE

HALOFANTRINE

  • CAS NO.:69756-53-2
  • Empirical Formula: C26H30Cl2F3NO
  • Molecular Weight: 500.42
  • MDL number: MFCD00866195
  • EINECS: 274-104-1
  • SAFETY DATA SHEET (SDS)
  • Update Date: 2024-11-19 23:02:33
HALOFANTRINE Structural

What is HALOFANTRINE?

Toxicity

Side effects incldue coughing noisy, rattling, troubled breathing, loss of appetite, aches and pain in joints, indigestion,and skin itching or rash.

Description

Halofantrine is an orally-active blood schizonticide reportedly highly effective in the treatment of fulcipurum malaria and other types of parasitemia. Cure rate is claimed to be over 95%.

Originator

Smith mine & French (USA)

Background

Halofantrine is an antimalarial. It belongs to the phenanthrene class of compounds that includes quinine and lumefantrine. It appears to inhibit polymerisation of heme molecules (by the parasite enzyme "heme polymerase"), resulting in the parasite being poisoned by its own waste. Halofantrine has been shown to preferentially block open and inactivated HERG channels leading to some degree of cardiotoxicity.

Indications

For treatment of Severe malaria

Definition

ChEBI: 3-(dibutylamino)-1-[1,3-dichloro-6-(trifluoromethyl)-9-phenanthrenyl]-1-propanol is a member of phenanthrenes.

brand name

Halfan

World Health Organization (WHO)

Halofantrine is an antimalarial introduced to medicine in 1982. It should be reserved for use in areas where multiple drug-resistant falciparum malaria is prevalent. Cases of serious cardiotoxicity have been reported.

Antimicrobial activity

It inhibits erythrocytic stages of chloroquine-sensitive and chloroquine-resistant P. falciparum and other Plasmodium spp. in vitro at concentrations of 0.4–4.0 mg/L. It is more active than mefloquine and the combination of proguanil and atovaquone against P. falciparum, but less effective than mefloquine or chloroquine against P. vivax.

Acquired resistance

Resistance in P. falciparum has been reported in Central and West Africa, where it has been used widely. Cross-resistance with mefloquine has been reported in Thailand, where it has not been used.

General Description

Structurally, halofantrine differs from allother antimalarial drugs. It is a good example of drug designthat incorporates bioisosteric principles as evidenced by thetrifluromethyl moiety. Halofantrine is a schizonticide and has no affect on the sporozoite, gametocyte,or hepatic stages. Both the parent compound and Ndesbutylmetabolite are equally active in vitro. Halfantrine’sspecific mechanism of action against the parasite is notknown. There is contradictory evidence that its mechanismranges from requiring heme to disrupting the mitochondria.There is a prominent warning that halfantrine can affectnerve conduction in cardiac tissue.

Pharmaceutical Applications

A phenanthrene methanol, formulated as the hydrochloride for oral administration. Parenteral formulations are not available. The enantiomers have equivalent activity in vitro. Aqueous solubility is extremely low.

Pharmacokinetics

Halofantrine is a synthetic antimalarial which acts as a blood schizonticide. It is effective against multi drug resistant (including mefloquine resistant) P. falciparum malaria.

Pharmacokinetics

Absorption shows high intra- and inter-subject variability and depends on co-administration with fats. Bioavailability is increased more than six-fold after a fatty meal or by lipidbased formulations. Bioavailability is significantly lower in patients with malaria than in healthy individuals. Peak plasma levels are variable and occur 3–6 h after administration. Unlike many other antimalarials, halofantrine is not concentrated by infected or uninfected erythrocytes. Distribution to lipoproteins is stereo-selective. About 20–30% of the dose is metabolized to an N-desbutyl derivative by cytochrome P450 (CYP) 3A4 and 3A5. The elimination half-life of the parent drug is generally 1–2 days and that of the metabolite 3 days. Little unchanged drug is excreted in urine.

Clinical Use

Treatment of multidrug-resistant falciparum malaria
Its use has been questioned due to the existence of safer alternatives.

Side Effects

Abdominal pain, diarrhea and pruritus are the most frequent. High doses (24 mg/kg) induce prolongation of the PR and QTc intervals; this is not stereo-selective. There are individual reports of fatal cardiac arrest and torsade de pointes. To reduce the risk of cardiac toxicity it should be taken on an empty stomach. It should not be administered with other antimalarials that have the potency to induce cardiac arrhythmias (mefloquine, chloroquine, quinine). Halofantrine has also been associated with intravascular hemolysis.

Metabolism

Hepatic

Metabolism

Halofantrine is considered to be an alternative drug for treatment of both chloroquine-sensitive and chloroquine-resistant Plasmodium falci parum malaria, but its efficacy in mefloquine-resistant malaria may be questionable. The drug is metabolized via N-dealkylation to desbutylhalofantrine by CYP3A4. The metabolite appears to be several-fold more active than the administered drug.

Properties of HALOFANTRINE

Density  1.244±0.06 g/cm3 (20 ºC 760 Torr)
storage temp.  2-8°C
Water Solubility  0.59mg/L(37 ºC)

Safety information for HALOFANTRINE

Computed Descriptors for HALOFANTRINE

Related products of tetrahydrofuran

You may like

  • Halofantrine HCl 98% (HPLC) CAS 69756-53-2
    Halofantrine HCl 98% (HPLC) CAS 69756-53-2
    69756-53-2
    View Details
  • 1975-50-4 98%
    1975-50-4 98%
    1975-50-4
    View Details
  • 2-HYDROXY BENZYL ALCOHOL 98%
    2-HYDROXY BENZYL ALCOHOL 98%
    90-01-7
    View Details
  • 2-Chloro-1,3-Bis(Dimethylamino)Trimethinium  Hexafluorophosphate 221615-75-4 98%
    2-Chloro-1,3-Bis(Dimethylamino)Trimethinium Hexafluorophosphate 221615-75-4 98%
    221615-75-4
    View Details
  • 61397-56-6 CIS BROMO BENZOATE 98%
    61397-56-6 CIS BROMO BENZOATE 98%
    61397-56-6
    View Details
  • 14714-50-2 (2-Hydroxyphenyl)acetonitrile 98+
    14714-50-2 (2-Hydroxyphenyl)acetonitrile 98+
    14714-50-2
    View Details
  • 118753-70-1 98+
    118753-70-1 98+
    118753-70-1
    View Details
  • 733039-20-8 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine 98+
    733039-20-8 5-broMo-2-chloro-N-cyclopentylpyriMidin-4-aMine 98+
    733039-20-8
    View Details
Statement: All products displayed on this website are only used for non medical purposes such as industrial applications or scientific research, and cannot be used for clinical diagnosis or treatment of humans or animals. They are not medicinal or edible.